SciSparc Ltd
Company Profile
Business description
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company’s operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact
20 Raul Wallenberg Street
Tower A, 2nd Floor
Tel Aviv6971916
ISRT: +972 37175777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,039.80 | 82.70 | -0.91% |
CAC 40 | 7,854.61 | 36.39 | 0.47% |
DAX 40 | 23,674.53 | 315.35 | 1.35% |
Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
FTSE 100 | 9,228.11 | 32.45 | 0.35% |
HKSE | 26,663.80 | 225.29 | 0.85% |
NASDAQ | 22,470.72 | 209.40 | 0.94% |
Nikkei 225 | 45,321.95 | 419.68 | 0.93% |
NZX 50 Index | 13,120.03 | 114.86 | -0.87% |
S&P 500 | 6,631.96 | 31.61 | 0.48% |
S&P/ASX 200 | 8,754.80 | 93.70 | -1.06% |
SSE Composite Index | 3,864.81 | 11.53 | -0.30% |